Company Analysis
Sign in

Cyclerion Therapeutics, Inc. (CYCN)

Nasdaq: CYCN · Pharmaceutical Preparations · Cambridge, MA · filing with the SEC since 2018
Full chart Alerts Compare
Grade4.9
◀ Past 4.2● Present 5.3▶ Future 5.1
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

24 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Cyclerion Therapeutics, Inc.’s names, not what it holds today.

Patents granted
24
24 utility, 1976 to Dec 31, 2025
Granted in 2025
2
Against 1 in 2024 and 6 in 2023
Applications published
49
7 of them in 2025
Names they are printed under
2
a former name
By yearGrantedApplications published
'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Organic fine chemistry11
Pharmaceuticals8
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Cyclerion Therapeutics, Inc. a former name
named as the applicant on its applications, in US
0 granted
47 published
Cyclerion Therapeutics, Inc. a former name
US, as the owner printed on each patent
24 granted
2 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Apr 15, 202512,275,724Processes and intermediates for the preparation of soluble guanylate cyclase stimulatorsOrganic fine chemistryCyclerion Therapeutics, Inc.
Mar 11, 202512,247,025Processes for preparation of soluble guanylate cyclase stimulatorsOrganic fine chemistryCyclerion Therapeutics, Inc.
Jul 9, 202412,030,874Processes and intermediates for the preparation of soluble guanylate cyclase stimulatorsOrganic fine chemistryCyclerion Therapeutics, Inc.
Dec 5, 202311,834,444Processes for preparation of soluble guanylate cyclase stimulatorsOrganic fine chemistryCyclerion Therapeutics, Inc.
Oct 3, 202311,773,089Process for preparation of soluble guanylate cyclase stimulatorsOrganic fine chemistryCyclerion Therapeutics, Inc.
Aug 22, 202311,731,977SGC stimulatorsPharmaceuticalsCyclerion Therapeutics, Inc.
Jul 25, 202311,708,361Processes and intermediates for the preparation of soluble guanylate cyclase stimulatorsOrganic fine chemistryCyclerion Therapeutics, Inc.
Jul 4, 202311,690,828Treatment of CNS diseases with sGC stimulatorsPharmaceuticalsCyclerion Therapeutics, Inc.
Feb 7, 202311,572,358Solid forms of an sGC stimulatorPharmaceuticalsCyclerion Therapeutics, Inc.
Oct 11, 202211,466,015Crystalline forms of 8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine as sGC stimulatorsOrganic fine chemistryCyclerion Therapeutics, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Nov 27, 20252025/0361228PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORSOrganic fine chemistryCyclerion Therapeutics, Inc.
Sep 11, 20252025/0282769SOLID FORMS OF AN SGC STIMULATORPharmaceuticalsCyclerion Therapeutics, Inc.
Aug 14, 20252025/0255821SOLID DISPERSIONS COMPRISING A SGC STIMULATORPharmaceuticalsCyclerion Therapeutics, Inc.
Jul 31, 20252025/0243228PHOSPHORUS PRODRUGS OF PYRAZOLO-SUBSTITUTED PYRIMIDINE sGC STIMULATORSPharmaceuticalsCyclerion Therapeutics, Inc.
Jul 31, 20252025/0243177sGC STIMULATORSPharmaceuticalsCyclerion Therapeutics, Inc.
Apr 24, 20252025/0129060SOLID FORMS OF AN SGC STIMULATORPharmaceuticalsCyclerion Therapeutics, Inc.
Jan 16, 20252025/0017862SOLID DISPERSIONS COMPRISING A SGC STIMULATORPharmaceuticalsCyclerion Therapeutics, Inc.
Nov 28, 20242024/0391911PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORSOrganic fine chemistryCyclerion Therapeutics, Inc. · patent 12,275,724 granted from it
Nov 7, 20242024/0366596TREATMENT OF HFPEF IN POST-MENOPAUSAL WOMEN WITH AN SGC STIMULATORPharmaceuticalsCyclerion Therapeutics, Inc.
Oct 31, 20242024/0360164PHOSPHORUS PRODRUGS OF PYRAZOLO-SUBSTITUTED PYRIMIDINE SGC STIMULATORSPharmaceuticalsCyclerion Therapeutics, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 14 · Organic fine chemistry 4.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton CYCN · research, not advice